While the Broad institute is private, it is a non-profit that is tightly affiliated with MIT and Harvard. To me, this is different than a patent getting transferred to a multinational pharmaceutical corporate.
Non-profits can still have patent portfolios that they try to exploit for commercial gain -- though by licensing, rather than producing products directly. When the research was publicly funded, the same conflicts of interest apply.
